Recent Updates — GERN

Geron Corporation announced the decision to discontinue its Phase 3 IMpactMF clinical trial evaluating imetelstat for JAK inhibitor relapsed/refractory myelofibrosis. The independent Data Monitoring Committee recommended stopping the study, advising that it was unlikely to meet its primary endpoint of overall survival. No new safety signals were observed that would alter the known safety profile of the drug. Geron plans to conduct a detailed analysis of the data and share findings with the scientific community at a future date. The company remains committed to growing demand for RYTELO in the U.S. and expanding access outside the U.S. Geron is a commercial-stage hematology biopharmaceutical company focused on blood cancer treatments.

Geron Corporation reported financial results for the quarter ended June 30, 2026, announcing RYTELO net product revenue of $57.5 million, an 11% increase from Q1 2026 and a 17% rise year-over-year. The company incurred a net loss of $16.7 million, or $0.02 per share, driven by non-cash inventory-related expenses that increased cost of goods sold to $9.2 million. Geron reiterated its full-year 2026 guidance, expecting RYTELO net product revenue between $220 million and $240 million and total operating expenses between $230 million and $240 million. The firm ended the quarter with approximately $327 million in cash and marketable securities. Additionally, Geron appointed Chinmaya Rath as Chief Business Officer to broaden its leadership team. Geron is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers.